FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220992493> ?p ?o ?g. }

• W4220992493 endingPage "e300" @default.
• W4220992493 startingPage "e289" @default.
• W4220992493 abstract "Background Novel therapies for relapsed or refractory follicular lymphoma are commonly evaluated in single-arm studies without formal comparison with other treatments or historical controls. Consequently, rigorously defined treatment outcomes informing expectations for novel therapeutic strategies in this population are sparse. To inform outcome expectations, we aimed to describe treatment patterns, survival outcomes, and duration of response in patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy. Methods In this multicentre cohort study, we developed a database of patients with relapsed or refractory follicular lymphoma from eight academic centres in the USA using data collected in the LEO Cohort study (NCT02736357) and the LEO Consortium. For this analysis, eligible patients were aged at least 18 years, had non-transformed grade 1–3a follicular lymphoma, and were receiving systemic therapy in the third line or later after previous therapy with an anti-CD20 antibody and an alkylating agent. Clinical data and patient outcomes were abstracted from medical records by use of a standard protocol. The index therapy for the primary analysis was defined as the first line of systemic therapy after the patient had received at least two previous systemic therapies that included an alkylating agent and an anti-CD20 therapy. The main endpoints of interest were overall response rate, progression-free survival, and overall survival. Outcomes were also evaluated in subsets of clinical interest (index therapy characteristics, patient and disease characteristics, treatment history, and best response assessment). Findings We screened 933 patients with follicular lymphoma, of whom 441 were included and diagnosed between March 6, 2002, and July 20, 2018. Index therapies included immunochemotherapy (n=133), anti-CD20 antibody monotherapy (n=53), lenalidomide with or without anti-CD20 (n=37), and phosphoinositide 3-kinase inhibitors with or without anti-CD20 (n=25). 57 (13%) of 441 patients received haematopoietic stem-cell transplantation and 98 (23%) of 421 patients with complete data received therapy on clinical trials. After a median follow-up of 71 months (IQR 64–79) from index therapy, 5-year overall survival was 75% (95% CI 70–79), median progression-free survival was 17 months (15–19), and the overall response rate was 70% (65–74; 280 of 400 patients evaluable for response). Patients who were refractory to therapy with an alkylating agent had a lower overall response rate (170 [68%] of 251 patients vs 107 [77%] of 139 patients) and a significantly lower 5-year overall survival (72%, 95% CI 66–78 vs 81%, 73–89; hazard ratio 1·60, 95% CI 1·04–2·46) than patients who were not refractory to therapy with an alkylating agent. Interpretation Patients with relapsed or refractory follicular lymphoma receive heterogeneous treatments in the third-line setting or later. We observed high response rates to contemporary therapies that were of short duration. These data identify unmet needs among patients with follicular lymphoma, especially those who are refractory to alkylating agents, and might provide evidence by which clinical trials evaluating novel treatments could be assessed. Funding Genentech and the National Cancer Institute." @default.
• W4220992493 created "2022-04-03" @default.
• W4220992493 creator A5001668616 @default.
• W4220992493 creator A5003296270 @default.
• W4220992493 creator A5007088786 @default.
• W4220992493 creator A5007477825 @default.
• W4220992493 creator A5025688165 @default.
• W4220992493 creator A5037878906 @default.
• W4220992493 creator A5038008601 @default.
• W4220992493 creator A5040141808 @default.
• W4220992493 creator A5041232356 @default.
• W4220992493 creator A5047509474 @default.
• W4220992493 creator A5047960113 @default.
• W4220992493 creator A5049069261 @default.
• W4220992493 creator A5055115466 @default.
• W4220992493 creator A5055368165 @default.
• W4220992493 creator A5062450132 @default.
• W4220992493 creator A5064738578 @default.
• W4220992493 creator A5068999622 @default.
• W4220992493 creator A5069054551 @default.
• W4220992493 creator A5076621021 @default.
• W4220992493 creator A5077867282 @default.
• W4220992493 creator A5082492795 @default.
• W4220992493 creator A5082892912 @default.
• W4220992493 creator A5083450833 @default.
• W4220992493 creator A5083592086 @default.
• W4220992493 date "2022-04-01" @default.
• W4220992493 modified "2023-10-06" @default.
• W4220992493 title "Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study" @default.
• W4220992493 cites W1927366038 @default.
• W4220992493 cites W2045330558 @default.
• W4220992493 cites W2046317078 @default.
• W4220992493 cites W2061272096 @default.
• W4220992493 cites W2074048861 @default.
• W4220992493 cites W2085346499 @default.
• W4220992493 cites W2108131857 @default.
• W4220992493 cites W2129200400 @default.
• W4220992493 cites W2134861285 @default.
• W4220992493 cites W2140056658 @default.
• W4220992493 cites W2141875764 @default.
• W4220992493 cites W2160093471 @default.
• W4220992493 cites W2169209759 @default.
• W4220992493 cites W2505010070 @default.
• W4220992493 cites W2518731208 @default.
• W4220992493 cites W2580592241 @default.
• W4220992493 cites W2615007676 @default.
• W4220992493 cites W2762226752 @default.
• W4220992493 cites W2784962174 @default.
• W4220992493 cites W2795961656 @default.
• W4220992493 cites W2891543930 @default.
• W4220992493 cites W2902350206 @default.
• W4220992493 cites W2913987637 @default.
• W4220992493 cites W2956178192 @default.
• W4220992493 cites W2963759094 @default.
• W4220992493 cites W2986196170 @default.
• W4220992493 cites W3043738734 @default.
• W4220992493 cites W3092484545 @default.
• W4220992493 cites W3095702079 @default.
• W4220992493 cites W3135092227 @default.
• W4220992493 cites W3211695207 @default.
• W4220992493 doi "https://doi.org/10.1016/s2352-3026(22)00033-3" @default.
• W4220992493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35358443" @default.
• W4220992493 hasPublicationYear "2022" @default.
• W4220992493 type Work @default.
• W4220992493 citedByCount "20" @default.
• W4220992493 countsByYear W42209924932022 @default.
• W4220992493 countsByYear W42209924932023 @default.
• W4220992493 crossrefType "journal-article" @default.
• W4220992493 hasAuthorship W4220992493A5001668616 @default.
• W4220992493 hasAuthorship W4220992493A5003296270 @default.
• W4220992493 hasAuthorship W4220992493A5007088786 @default.
• W4220992493 hasAuthorship W4220992493A5007477825 @default.
• W4220992493 hasAuthorship W4220992493A5025688165 @default.
• W4220992493 hasAuthorship W4220992493A5037878906 @default.
• W4220992493 hasAuthorship W4220992493A5038008601 @default.
• W4220992493 hasAuthorship W4220992493A5040141808 @default.
• W4220992493 hasAuthorship W4220992493A5041232356 @default.
• W4220992493 hasAuthorship W4220992493A5047509474 @default.
• W4220992493 hasAuthorship W4220992493A5047960113 @default.
• W4220992493 hasAuthorship W4220992493A5049069261 @default.
• W4220992493 hasAuthorship W4220992493A5055115466 @default.
• W4220992493 hasAuthorship W4220992493A5055368165 @default.
• W4220992493 hasAuthorship W4220992493A5062450132 @default.
• W4220992493 hasAuthorship W4220992493A5064738578 @default.
• W4220992493 hasAuthorship W4220992493A5068999622 @default.
• W4220992493 hasAuthorship W4220992493A5069054551 @default.
• W4220992493 hasAuthorship W4220992493A5076621021 @default.
• W4220992493 hasAuthorship W4220992493A5077867282 @default.
• W4220992493 hasAuthorship W4220992493A5082492795 @default.
• W4220992493 hasAuthorship W4220992493A5082892912 @default.
• W4220992493 hasAuthorship W4220992493A5083450833 @default.
• W4220992493 hasAuthorship W4220992493A5083592086 @default.
• W4220992493 hasBestOaLocation W42209924931 @default.
• W4220992493 hasConcept C121332964 @default.
• W4220992493 hasConcept C121608353 @default.
• W4220992493 hasConcept C126322002 @default.
• W4220992493 hasConcept C142424586 @default.
• W4220992493 hasConcept C143998085 @default.

• next